The International Bone and Mineral Society gratefully acknowledges the support of its 2008 partners:
The Alliance for Better Bone Health | Amgen | Chugai Pharmaceutical
GSK | Lilly | Merck | Novartis | Nycomed
Pfizer | Roche | Teijin | Wyeth
Information about Amgen Inc. is available at .
Chugai Pharmaceutical aspires for development of innovative drugs by integrating cutting-edge technologies into its unique drug discovery infrastructure. Funneling resources into prescription drugs, Chugai is pursuing research and development of antibody drug-centered biopharmaceuticals in five franchises; cancer, renal, cardiovascular, bone/joint, and transplantation/immunology/infectious diseases while actively working on the traditional chemical cynthesis drug discovery. Based on high ethical and moral standards for a life science enterprise, Chugai, with its Patient-First philosophy, is committed to contributing to society by developing innovative drugs enabling higher patients' QOL and better lives.
Additional information about Chugai is available at .
Eli Lilly and Company is a leading, innovation-driven corporation committed to developing a growing portfolio of best-in-class and first-in-class pharmaceutical products that help people live longer, healthier and more active lives. Lilly products treat depression, schizophrenia, attention-deficit hyperactivity disorder, diabetes, osteoporosis and many other conditions. We are committed to providing answers that matter - through medicines and information - for some of the world's most urgent medical needs.
Additional information about Lilly is available at .
Information about GSK is available at .
Merck, Sharp, and Dohme, Inc. (MSD) is a global, research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human health products. MSD, the manufacturer of FOSAMAX® (alendronate sodium), is a leader in osteoporosis research and treatment.
Additional information about MSD is available at .
Information about Novartis is available at .
Nycomed is a European pharmaceutical company. Rapidly expanding, Nycomed now operates in 19 European countries including Russia / CIS. We provide hospital/specialist products throughout Europe and GP & OTC products in selected markets. Within the field of osteoporosis, Nycomed is currently partnering with NPS pharmaceuticals on the development of full-length PTH (1-84) which stimulates growth of structurally-normal bone lost to the disease. This product is expected to further strengthen Nycomed’s existing osteoporosis position built through its Nycomed Calcium & Vitamin D3 portfolio.
If you want to learn more about us please visit our website:
Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world’s best-known consumer products. Pfizer Global Research and Development (PGRD) is the R&D division of Pfizer Inc. PGRD, the world’s largest private biomedical research organization, is headquartered in New London, Connecticut and has over 160 research projects in the following areas: antibacterials, antivirals, antifungals, arthritis, allergy and respiratory diseases, atherosclerosis, cardiovascular diseases, cancer, diabetes, gastrointestinal diseases, immunological diseases, metabolic diseases, neurodegenerative diseases, obesity, opthamological diseases, osteoporosis, pain research, psychotherapeutic research and sexual health/urology.
Additional information about Pfizer is available at .
Roche's Pharmaceuticals Division discovers, develops, manufactures and markets prescription drugs for the following therapeutic areas: osteoporosis, central nervous system, infectious diseases, oncology, virology, cardiovascular diseases, inflammatory and autoimmune diseases, dermatology, metabolic disorders and respiratory diseases. The division also plays an active role in the field of self-medication, where Roche Consumer Health is a market leader in many countries around the world. It is Roche's mission to provide innovative medicines that address currently unmet medical needs or improve on existing therapies.
Additional information about Roche is available at .
Information about Teijin is available at
Wyeth Pharmaceuticals is a major research-oriented pharmaceutical company with leading products in the areas of women’s health care, cardiovascular disease therapies, central nervous system drugs, musculosketetal therapies, infectious disease, hemophilia, oncology, and vaccines. As a world leader in women’s health care, the company is committed to women through ongoing research efforts and patient education programs.
Additional information about Wyeth is available at .
2008 BoneKEy Sponsors
Information about Amgen Inc. is available at .
Information about Procter & Gamble Pharmaceuticals is available at .
Information about Sanofi aventis is available at .
Information about Novartis is available at .
Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines, for humans and animals, and many of the world’s best-known consumer products. Pfizer Global Research and Development (PGRD) is the R&D division of Pfizer Inc. PGRD, the world’s largest private biomedical research organization, is headquartered in New London, Connecticut and has over 160 research projects in the following areas: antibacterials, antivirals, antifungals, arthritis, allergy and respiratory diseases, atherosclerosis, cardiovascular diseases, cancer, diabetes, gastrointestinal diseases, immunological diseases, metabolic diseases, neurodegenerative diseases, obesity, opthamological diseases, osteoporosis, pain research, psychotherapeutic research and sexual health/urology.
Additional information about Pfizer is available at .
Wyeth Pharmaceuticals is a major research-oriented pharmaceutical company with leading products in the areas of women’s health care, cardiovascular disease therapies, central nervous system drugs, musculosketetal therapies, infectious disease, hemophilia, oncology, and vaccines. As a world leader in women’s health care, the company is committed to women through ongoing research efforts and patient education programs.
Additional information about Wyeth is available at .
2008 Collective Membership Society Sponsors
Nycomed is a European pharmaceutical company. Rapidly expanding, Nycomed now operates in 19 European countries including Russia / CIS. We provide hospital/specialist products throughout Europe and GP & OTC products in selected markets. Within the field of osteoporosis, Nycomed is currently partnering with NPS pharmaceuticals on the development of full-length PTH (1-84) which stimulates growth of structurally-normal bone lost to the disease. This product is expected to further strengthen Nycomed’s existing osteoporosis position built through its Nycomed Calcium & Vitamin D3 portfolio.
If you want to learn more about us please visit our website: